Browse the corpus

Salmon calcitonin, hereinafter referred to as calcitonin, is a derivative of human calcitonin utilized for the management of postmenopausal osteoporosis, Paget disease of bone, and hypercalcemia. Calcitonin is a peptide hormone consisting of 32 amino acids, primarily synthesized by the parafollicular cells (C cells) of the human thyroid gland. Extensive research has been conducted on salmon calcitonin, revealing its heightened potency compared to the human variant, thus establishing it as the preferred option in clinical application. The drug's clinical significance derives from its ability to inhibit osteoclast activity and increase renal excretion of calcium. Through these mechanisms, the resorption of bone matrix and serum calcium levels are diminished. Owing to these reasons, calcitonin proves advantageous in addressing the aforementioned conditions. This activity reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacokinetics, and monitoring recommendations of calcitonin to enhance the competence of interprofessional healthcare team members when caring for patients with postmenopausal osteoporosis, Paget disease of bone, and hypercalcemia. Objectives: Identify the appropriate indications for calcitonin therapy, including postmenopausal osteoporosis, Paget disease of bone, and hypercalcemia. Screen patients for contraindications, allergies, and potential interactions before initiating calcitonin therapy. Implement proper patient dosing regimens based on specific clinical conditions and patient characteristics. Coordinate the patient care plan with the interprofessional team to manage potential drug interactions and optimize treatment outcomes. Access free multiple choice questions on this topic.

A weak association is observed between the extended usage of intranasal calcitonin and an increased incidence of cancer, particularly basal cell carcinoma. A comprehensive meta-analysis of 21 randomized, controlled clinical trials unveiled a higher occurrence of malignancy in individuals treated with calcitonin (4.1%) compared to those administered a placebo (2.9%).[1][29] Animal studies have demonstrated an increased incidence of pituitary hyperplasia and adenomas with high calcitonin dosages. However, preclinical investigations involving the overexpression of salmon calcitonin in transgenic mice have not provided any indication of the molecule acting as a carcinogen.[30] Calcitonin has also demonstrated the absence of mutagenic properties when exposed to Salmonella and Escherichia coli cells. Furthermore, based on the current comprehension of calcitonin's mechanisms of action, there is no plausible mechanism of causality.[31][32] Although the association between calcitonin usage and cancer remains tenuous, it is advisable to carefully contemplate treatment alternatives with more favorable risk-to-benefit profiles before initiating pharmacotherapy. Considering calcitonin's mechanisms of action, the drug may also induce hypocalcemia. Hypocalcemia can trigger symptoms such as tetany, seizures, changes in mental status, and even cardiac arrest. Patients should incorporate supplementary vitamin D and calcium into their regimen when utilizing calcitonin to manage Paget disease of bone or postmenopausal osteoporosis to avert the onset of hypocalcemia. Men between the ages of 50 and 70 should consider a daily calcium intake of 1000 mg, whereas women older than 50 and men older than 70 should take 1200 mg of calcium daily. Individuals aged 50 or older should take 800 to 1000 units of vitamin D daily, whereas those aged 70 or older should reduce their daily vitamin D intake to 800 units.[1] Combining calcitonin and bisphosphonates can offer therapeutic advantages in managing hypercalcemia. However, this approach necessitates caution, as it can potentially lead to hypocalcemia, especially when using zoledronate.[33]

When initiating calcitonin therapy for patients with acute hypercalcemia, Paget disease of bone, and postmenopausal osteoporosis, a collaborative healthcare approach involving an interprofessional team is essential. This healthcare team should include the patient's primary care physician, endocrinologist, oncologist, advanced practice practitioners, nursing staff, and clinical pharmacist to provide a comprehensive approach toward patient care. Close monitoring of patients' conditions is crucial throughout calcitonin therapy to uphold the safety of patients and enhance their treatment outcomes. Interprofessional collaboration facilitates consistent monitoring of the patient's treatment response, encompassing evaluations of bone density, serum calcium levels, and the occurrence of adverse effects. Effective communication and coordination with shared decision-making among healthcare professionals enable timely modifications in dosage, treatment duration, or adjunctive therapies when necessary. This approach optimizes the medication's potential therapeutic effectiveness while minimizing adverse events.